Prokaynamyd

When ATH:
C01BA02

Characteristic.

White or white with a yellowish or creamy tint crystalline powder. Very easily soluble in water, easily - in alcohol. Aqueous solution - colorless transparent fluid.

Pharmacological action.
Antiarrhythmic.

Application.

Auricular flutter, Paroxysmal atrial fibrillation, ventricular premature beats, ventricular tachycardia.

Contraindications.

Hypersensitivity, OF блокада, bundle-branch block, intoxication serdechnыmi glikozidami, heart failure, abnormalities in the liver and kidneys, systemic lupus erythematosus, bronchial asthma, myasthenia.

Side effects.

Hypotension, asistolija, OF блокада, lupus syndrome, hemolytic anemia with a positive Coombs test, agranulocytosis, dyspepsia, dizziness, drowsiness, depression, psychotic reactions with productive symptoms, allergic reactions.

Cooperation.

Enhances the effect of antiarrhythmic drugs, anticholinergic and cytostatic agents, muscle relaxants, bretylium side effects. Reduces the activity of antimyasthenic drugs.

Overdose.

Symptoms: confusion, decreased urination, severe dizziness or fainting, fast or irregular heartbeat, nausea or vomiting.

Treatment: gastric lavage, induction of vomiting, hemodialysis, vasoconstrictors and airway maintenance.

Dosing and Administration.

For atrial arrhythmias, enterally - 1250 mg dose, then 500–1000 mg every 2–3 hours until the attack stops. Maintenance therapy - 500-1000 mg every 4-6 hours. For ventricular arrhythmias - 1000 mg dose, then in a daily dose based on 50 mg / kg 8 receptions. The highest daily dose - 3 g. / M 50 mg/kg per day in divided doses every 3–6 hours. To relieve paroxysmal tachycardia, 200–500 mg IV at a rate of 50–100 mg/min.

Precautions.

Due to the possible inhibition of myocardial contractility and a decrease in blood pressure, it should be used with great caution during myocardial infarction.. Not recommended for severe heart failure and severe atherosclerosis. When using procainamide in pregnant women, there is a potential risk of accumulation and development of maternal hypotension, which can lead to uteroplacental insufficiency. Be careful when driving or performing work, requiring attention.

Cooperation

Active substanceDescription of interaction
Gidroxlorotiazid + CaptoprilFMR. Strengthen (mutually) the risk of leukopenia (granoulozitopenia).
Gidroxlorotiazid + FosinoprilFMR. Strengthen (mutually) the risk of leukopenia (granoulozitopenia).

Back to top button